Drug intelligence / Profile preview

FL-103

Development stage: Unknown
Lead developer: Leap Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

FL-103 is a proprietary IL-1ß antibody. It was originally part of the pipeline of Flame Biosciences. Leap Therapeutics acquired Flame Biosciences in January 2023, thereby gaining FL-103. In December 2023, Leap Therapeutics and Flame Biosciences sold FL-103, along with FL-101, to AlmataBio. The drug is being developed as a therapeutic agent, likely for conditions involving IL-1ß mediated inflammation.

Targets

IL1B (Interleukin-1 beta)

Beyond the preview

Go deeper on FL-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FL-103.

Explore the full profile